Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

Imagem de Miniatura
Arquivos
art_ANDRADE_Pregabalin_for_the_Prevention_of_OxaliplatinInduced_Painful_Neuropathy_2017.PDF (387.83 KB)
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
MILENO, Paula Braz
Citação
ONCOLOGIST, v.22, n.10, p.1154-0, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin-induced peripheral neuropathy (OXAIPN). Acute and chronic OXA-related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: central sensitization (CS) of nociceptive neuronal networks, leading to increased sensitivity (hyperlgesia, allodynia) in the somatosensory system, the common ground of chronic neuropathic pain. Because CS is related to increased risk of painful OXAIPN, we hypothesized that preemptive use of the anti-hyperalgesic drug pregabaline (known to decrease CS) during OXA infusions would decrease the incidence of chronic OXAIPN. Methods. Pain-free, chemotherapy-naive CRC patients receiving at least one cycle of modified-FLOX [5-FU(500 mg/m(2)) 1 leucovorin(20 mg/m(2))/week for] 6 weeks+oxaliplatin(85 mg/m2) at weeks 1-3-5 every 8 weeks] were randomized (1:1) into the study. Patients received either pregabalin or placebo for 3 days before and 3 days after each OXA infusion and were followed for up to 6 months. Clinical assessments were performed at baseline, at the end of chemotherapy, and after the follow-up period. The main outcome was average pain at the last visit assessed by the visual analogic scale (0-10) item of the Brief Pain Inventory (BPI). Secondary endpoints were presence of neuropathic pain according to the Douleur Neuropathique-4 (DN-4), pain dimensions (short-form McGill Pain Questionnaire [MPQ]), Neuropathic Pain Symptom Inventory (NPSI), and changes in nerve conduction studies (NCS) and side effect profile. Results. One hundred ninety-nine patients (57.0 +/- 10.7 years old, 98 female, 101 male) were randomized. Data from 56 patients were not included in the analyses (as they did not receive at least one full cycle of modified FLOX). Data from 78 patients in the pregabalin group and 65 patients in the placebo group were retained for analyses. At the last visit, pain intensity in the pregabalin group was 1.03 (95% confidence interval [CI] 50.79-1.26), and 0.85 (95% CI50.64-1.06) in the placebo group, which did not reach significance. Scores from the BPI, MPQ, DN-4, NPSI, and NCS and side-effect profiles and incidence of death did not differ between groups. Quality of life (QoL) score did not differ between groups (placebo = 576.9 +/- 23.1, pregabalin group 79.4 +/- 20.6). Mood scores were not significantly different between groups (placebo 9.7 [8.1-11.2]; pregabalin 6.8 [5.6-8.0]). Conclusion. The preemptive use of pregabalin during OXA infusions was safe, but did not decrease the incidence of chronic pain related to OXAIPN.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/24296
Referências
  1. Argyriou AA, 2006, NEUROLOGY, V67, P2253, DOI 10.1212/01.wnl.0000249344.99671.d4
  2. Attal N, 2009, PAIN, V144, P245, DOI 10.1016/j.pain.2009.03.024
  3. Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
  4. Buvanendran A, 2010, REGION ANESTH PAIN M, V35, P535, DOI 10.1097/AAP.0b013e3181fa6b7a
  5. Buvanendran A, 2010, ANESTH ANALG, V110, P199, DOI 10.1213/ANE.0b013e3181c4273a
  6. Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061
  7. Cavaletti G, 2003, NEUROLOGY, V61, P1297
  8. Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
  9. Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
  10. de Afonseca SO, 2013, SAO PAULO MED J, V131, P35, DOI 10.1590/S1516-31802013000100006
  11. de Andrade DC, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-107
  12. Durand JP, 2012, ANN ONCOL, V23, P200, DOI 10.1093/annonc/mdr045
  13. Gamelin L, 2004, CLIN CANCER RES, V10, P4055, DOI 10.1158/1078-0432.CCR-03-0666
  14. Grothey A, 2011, J CLIN ONCOL, V29, P421, DOI 10.1200/JCO.2010.31.5911
  15. Guo XD, 2008, STEREOT FUNCT NEUROS, V86, P237, DOI 10.1159/000131662
  16. Hansen N, 2012, SCHMERZ, V26, P8, DOI 10.1007/s00482-011-1117-1
  17. Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
  18. Kautio AL, 2009, ANTICANCER RES, V29, P2601
  19. Kono T, 2013, CANCER CHEMOTH PHARM, V72, P1283, DOI 10.1007/s00280-013-2306-7
  20. Kuhn M., 2013, APPL PREDICTIVE MODE
  21. Kus T, 2016, SUPPORT CARE CANCER, V24, P2085, DOI 10.1007/s00520-015-3009-x
  22. Loprinzi CL, 2014, J CLIN ONCOL, V32, P997, DOI 10.1200/JCO.2013.52.0536
  23. MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
  24. Mihara Y, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-8
  25. Nagashima M, 2014, SUPPORT CARE CANCER, V22, P1579, DOI 10.1007/s00520-014-2132-4
  26. National Cancer Institute, 2003, COMM TERM CRIT ADV E
  27. Nikolajsen L, 1997, PAIN, V72, P393, DOI 10.1016/S0304-3959(97)00061-4
  28. PAATERO P, 1994, ENVIRONMETRICS, V5, P111, DOI 10.1002/env.3170050203
  29. Penz M, 2001, ANN ONCOL, V12, P421, DOI 10.1023/A:1011184609963
  30. Prantner B, 2011, VISUALIZATION IMPUTE
  31. Rao RD, 2007, CANCER, V110, P2110, DOI 10.1002/cncr.23008
  32. Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438
  33. Santos JG, 2010, J PAIN, V11, P484, DOI 10.1016/j.jpain.2009.09.014
  34. Ferreira KAS, 2013, PAIN MANAG NURS, V14, P210, DOI 10.1016/j.pmn.2011.04.006
  35. Schmidt PC, 2013, ANESTHESIOLOGY, V119, P1215, DOI 10.1097/ALN.0b013e3182a9a896
  36. Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
  37. Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59
  38. Ventzel L, 2016, PAIN, V157, P560, DOI 10.1097/j.pain.0000000000000404
  39. Zeilig G, 2012, BRAIN, V135, P418, DOI 10.1093/brain/awr270
  40. ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Carregar mais